StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Indirect Research and Development Expenses by Quarter

Indirect Research and Development Expenses — Total ($M) ($M)

Regeneron Pharmaceuticals Indirect Research and Development Expenses: $724M in Q3 2026, up 7.7% from a year earlier. That is the highest of the 39 quarters on record here.

Latest, Q3 2026
724
Period ended Sep 30, 2026
Change on a year earlier
+7.7%
672 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“R&D Expenses Table (FY2026Q3): Total indirect research and development expenses | 723.9 | 672.1 | 51.8 | 2,152.1 | 2,011.1 | 141.0”

Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIndirect Research and Development Expenses — Total ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026724+7.7%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 2026714+6.1%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 2026714+7.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025683+0.7%Form 10-K (regn-20251231.htm; 0000872589-26-000034|regn-20260930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025672+6.8%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 2025673+8.4%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 2025666+9.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 2024679+12.4%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 2024630+14.9%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 2024621+14.2%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 2024609+6.8%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023604+17.2%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 2023548+15.9%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023544+19.5%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 2023571+29.1%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 2022515+21.6%Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗

Breakdown

What makes up indirect Research and Development Expenses

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Indirect Research and Development Expenses ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-indirect-tot

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?